DK2448950T3 - SYNTHESIS OF N4- (2,2-dimethyl-4 - [(dihydrogen phosphonoxy) methyl] -3-oxo-5-pyrido [1,4] oxazin-6-yl) -5-fluoro-N2- (3,4 , 5-trimethoxyphenyl) -2,4-PYRIMIDINDIAMINDINATRIUMSALT - Google Patents
SYNTHESIS OF N4- (2,2-dimethyl-4 - [(dihydrogen phosphonoxy) methyl] -3-oxo-5-pyrido [1,4] oxazin-6-yl) -5-fluoro-N2- (3,4 , 5-trimethoxyphenyl) -2,4-PYRIMIDINDIAMINDINATRIUMSALT Download PDFInfo
- Publication number
- DK2448950T3 DK2448950T3 DK10730679.7T DK10730679T DK2448950T3 DK 2448950 T3 DK2448950 T3 DK 2448950T3 DK 10730679 T DK10730679 T DK 10730679T DK 2448950 T3 DK2448950 T3 DK 2448950T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- amide
- solvate
- conditions suitable
- Prior art date
Links
- -1 [1,4] oxazin-6-yl Chemical group 0.000 title claims description 12
- 230000015572 biosynthetic process Effects 0.000 title description 14
- 238000003786 synthesis reaction Methods 0.000 title description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title description 7
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 88
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 60
- 239000012453 solvate Substances 0.000 claims description 54
- 150000001408 amides Chemical class 0.000 claims description 52
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 150000004687 hexahydrates Chemical class 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 150000003511 tertiary amides Chemical class 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910001415 sodium ion Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 150000003334 secondary amides Chemical class 0.000 claims description 2
- LNJAJHJFSKUCIR-UHFFFAOYSA-N ditert-butyl chloromethyl phosphate Chemical group CC(C)(C)OP(=O)(OCCl)OC(C)(C)C LNJAJHJFSKUCIR-UHFFFAOYSA-N 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 22
- 229910019142 PO4 Inorganic materials 0.000 description 20
- 235000021317 phosphate Nutrition 0.000 description 20
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 17
- 239000010452 phosphate Substances 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 239000003444 phase transfer catalyst Substances 0.000 description 11
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical compound ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000001382 dynamic differential scanning calorimetry Methods 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GGYVTHJIUNGKFZ-UHFFFAOYSA-N 1-methylpiperidin-2-one Chemical compound CN1CCCCC1=O GGYVTHJIUNGKFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BHFLSZOGGDDWQM-UHFFFAOYSA-N 1h-benzimidazole;carbamic acid Chemical class NC(O)=O.C1=CC=C2NC=NC2=C1 BHFLSZOGGDDWQM-UHFFFAOYSA-N 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003421 catalytic decomposition reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27007309P | 2009-07-02 | 2009-07-02 | |
| PCT/US2010/040792 WO2011002999A1 (en) | 2009-07-02 | 2010-07-01 | Synthesis of n4- (2, 2-dimethyl-4- [ (dihydrogen phosphonoxy ] -3-oxo-5-pyrido [1, 4] oxazin-6-yl)-5-fluoro-n2- (3, 4, 5,-trimethoxyphenyl) -2, 4- pyrimidinediamine disodium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2448950T3 true DK2448950T3 (en) | 2016-04-04 |
Family
ID=42937685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10730679.7T DK2448950T3 (en) | 2009-07-02 | 2010-07-01 | SYNTHESIS OF N4- (2,2-dimethyl-4 - [(dihydrogen phosphonoxy) methyl] -3-oxo-5-pyrido [1,4] oxazin-6-yl) -5-fluoro-N2- (3,4 , 5-trimethoxyphenyl) -2,4-PYRIMIDINDIAMINDINATRIUMSALT |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8299242B2 (enExample) |
| EP (1) | EP2448950B1 (enExample) |
| JP (1) | JP5739882B2 (enExample) |
| CN (1) | CN102482305B (enExample) |
| AU (1) | AU2010266213B2 (enExample) |
| BR (1) | BRPI1011888A2 (enExample) |
| CA (1) | CA2766801C (enExample) |
| CY (1) | CY1117489T1 (enExample) |
| DK (1) | DK2448950T3 (enExample) |
| EA (1) | EA021657B1 (enExample) |
| ES (1) | ES2565985T3 (enExample) |
| HR (1) | HRP20160319T1 (enExample) |
| HU (1) | HUE027212T2 (enExample) |
| ME (1) | ME02388B (enExample) |
| PL (1) | PL2448950T3 (enExample) |
| RS (1) | RS54679B1 (enExample) |
| SG (1) | SG176799A1 (enExample) |
| SI (1) | SI2448950T1 (enExample) |
| SM (1) | SMT201600084B (enExample) |
| UA (1) | UA108077C2 (enExample) |
| WO (1) | WO2011002999A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5468899B2 (ja) | 2006-07-20 | 2014-04-09 | アフィニウム ファーマシューティカルズ， インク． | Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 |
| UA108077C2 (xx) | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
| US20110206661A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| EP2736487B2 (en) * | 2011-07-28 | 2024-08-28 | Rigel Pharmaceuticals, Inc. | New (trimethoxyphenylamino)pyrimidinyl formulations |
| TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| MY170437A (en) | 2012-06-19 | 2019-07-31 | Debiopharm Int Sa | Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
| CN102746337B (zh) * | 2012-06-21 | 2014-12-17 | 成都苑东药业有限公司 | 一种2，4-嘧啶二胺类化合物及其制备方法 |
| TW201410657A (zh) | 2012-08-02 | 2014-03-16 | Endo Pharmaceuticals Inc | 經取代胺基－嘧啶衍生物 |
| LT3083648T (lt) * | 2013-12-20 | 2019-01-25 | Rigel Pharmaceuticals, Inc. | Farmacinis būdas ir tarpiniai junginiai |
| PL3419628T3 (pl) | 2016-02-26 | 2021-05-31 | Debiopharm International Sa | Lek do leczenia zakażeń stopy cukrzycowej |
| EP3509578B1 (en) | 2016-09-08 | 2022-12-21 | Glykon Technologies Group, LLC | Monomeric bimetal hydroxycitric acid compounds and methods of making and using the same |
| JP2020536100A (ja) * | 2017-10-04 | 2020-12-10 | セルジーン コーポレイション | シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス |
| HRP20230437T1 (hr) | 2019-02-14 | 2023-07-07 | Debiopharm International S.A. | Formulacija afabicina, postupak izrade iste |
| CN113939306B (zh) | 2019-06-14 | 2024-07-19 | 德彪药业国际股份公司 | 用于治疗涉及生物膜的细菌感染的药物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US303022A (en) | 1884-08-05 | Egg-beater | ||
| US324087A (en) | 1885-08-11 | Abel combs | ||
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20040024716A1 (en) | 2002-04-12 | 2004-02-05 | James Malatesta | Mail sorting processes and systems |
| CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| US20060047135A1 (en) | 2004-08-30 | 2006-03-02 | Chadwick Scott T | Process for preparing chloromethyl di-tert-butylphosphate |
| US7449458B2 (en) * | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US20090114877A1 (en) * | 2005-09-13 | 2009-05-07 | Eisai R&D Management Co., Ltd. | Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same |
| US8163902B2 (en) * | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| UA108077C2 (xx) | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну |
-
2010
- 2010-01-07 UA UAA201201072A patent/UA108077C2/ru unknown
- 2010-07-01 EP EP10730679.7A patent/EP2448950B1/en active Active
- 2010-07-01 PL PL10730679T patent/PL2448950T3/pl unknown
- 2010-07-01 HR HRP20160319TT patent/HRP20160319T1/hr unknown
- 2010-07-01 BR BRPI1011888A patent/BRPI1011888A2/pt not_active Application Discontinuation
- 2010-07-01 US US12/829,126 patent/US8299242B2/en active Active
- 2010-07-01 CN CN201080039108.1A patent/CN102482305B/zh active Active
- 2010-07-01 WO PCT/US2010/040792 patent/WO2011002999A1/en not_active Ceased
- 2010-07-01 HU HUE10730679A patent/HUE027212T2/en unknown
- 2010-07-01 DK DK10730679.7T patent/DK2448950T3/en active
- 2010-07-01 JP JP2012518607A patent/JP5739882B2/ja active Active
- 2010-07-01 AU AU2010266213A patent/AU2010266213B2/en active Active
- 2010-07-01 SG SG2011091733A patent/SG176799A1/en unknown
- 2010-07-01 SI SI201031148A patent/SI2448950T1/sl unknown
- 2010-07-01 RS RS20160220A patent/RS54679B1/sr unknown
- 2010-07-01 EA EA201270114A patent/EA021657B1/ru unknown
- 2010-07-01 ES ES10730679.7T patent/ES2565985T3/es active Active
- 2010-07-01 ME MEP-2016-57A patent/ME02388B/me unknown
- 2010-07-01 CA CA2766801A patent/CA2766801C/en active Active
-
2012
- 2012-09-24 US US13/625,552 patent/US8481724B2/en active Active
-
2013
- 2013-06-07 US US13/912,856 patent/US8691798B2/en active Active
-
2016
- 2016-03-24 SM SM201600084T patent/SMT201600084B/xx unknown
- 2016-04-12 CY CY20161100304T patent/CY1117489T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102482305B (zh) | 2016-07-13 |
| CA2766801C (en) | 2018-03-13 |
| US20110003986A1 (en) | 2011-01-06 |
| CN102482305A (zh) | 2012-05-30 |
| BRPI1011888A2 (pt) | 2016-04-12 |
| US20130274499A1 (en) | 2013-10-17 |
| HRP20160319T1 (hr) | 2016-04-22 |
| AU2010266213A1 (en) | 2012-02-02 |
| SI2448950T1 (sl) | 2016-05-31 |
| JP5739882B2 (ja) | 2015-06-24 |
| HUE027212T2 (en) | 2016-10-28 |
| RS54679B1 (sr) | 2016-08-31 |
| WO2011002999A1 (en) | 2011-01-06 |
| EP2448950A1 (en) | 2012-05-09 |
| AU2010266213B2 (en) | 2015-06-18 |
| CY1117489T1 (el) | 2017-04-26 |
| EP2448950B1 (en) | 2016-01-13 |
| US8691798B2 (en) | 2014-04-08 |
| SMT201600084B (it) | 2016-04-29 |
| EA021657B1 (ru) | 2015-08-31 |
| US8481724B2 (en) | 2013-07-09 |
| CA2766801A1 (en) | 2011-01-06 |
| US8299242B2 (en) | 2012-10-30 |
| EA201270114A1 (ru) | 2012-05-30 |
| ME02388B (me) | 2016-09-20 |
| PL2448950T3 (pl) | 2016-06-30 |
| SG176799A1 (en) | 2012-01-30 |
| US20130018185A1 (en) | 2013-01-17 |
| UA108077C2 (xx) | 2015-03-25 |
| HK1169996A1 (zh) | 2013-02-15 |
| ES2565985T3 (es) | 2016-04-08 |
| JP2012532143A (ja) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2448950T3 (en) | SYNTHESIS OF N4- (2,2-dimethyl-4 - [(dihydrogen phosphonoxy) methyl] -3-oxo-5-pyrido [1,4] oxazin-6-yl) -5-fluoro-N2- (3,4 , 5-trimethoxyphenyl) -2,4-PYRIMIDINDIAMINDINATRIUMSALT | |
| EP2462935B1 (en) | Process for the preparation of tenofovir | |
| JP5142716B2 (ja) | サイクリックエステルのルイス酸介在合成法 | |
| KR20010085855A (ko) | 항바이러스성 퓨린 유도체들 | |
| WO2017029594A1 (en) | Processes for preparation of selexipag and its amorphous form | |
| JP2017214378A (ja) | ホスホン酸エステル誘導体およびその合成方法 | |
| ES2539908T3 (es) | Métodos de preparación de un compuesto profármaco inhibidor de la fijación del VIH e intermedios | |
| JP2013528200A (ja) | エステルアミド化合物を調製する方法 | |
| CN115968370A (zh) | Iap拮抗剂化合物和中间体及其合成方法 | |
| CN111606889A (zh) | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 | |
| US20170354668A1 (en) | Synthesis Method For Improved Tenofovir Disoproxil Fumarate Using Ion-Exchange Resin And Method For Preparing Oral Dissolving Film Form Using The Same | |
| CN112955449A (zh) | 制备bet溴结构域抑制剂的固体形式的方法 | |
| HK1169996B (en) | Synthesis of n4- (2, 2-dimethyl-4- [(dihydrogen phosphonoxy)methyl]-3-oxo-5-pyrido [1, 4]oxazin-6-yl)-5-fluoro-n2- (3, 4, 5,-trimethoxyphenyl)-2, 4- pyrimidinediamine disodium salt | |
| ES2433218T3 (es) | Fenil-alquil piperazinas que tienen una actividad moduladora de TNF | |
| CN106132972B (zh) | 用于治疗hcv感染的氨基磷酸酯 | |
| JP6750613B2 (ja) | プリノン誘導体の製造方法 | |
| FI124449B (fi) | Endoteliinireseptorin vastavaikuttajan valmistusprosessi | |
| HK40125773A (zh) | Iap拮抗剂化合物和中间体及其合成方法 | |
| TW200522961A (en) | New process for preparing diisopropyl ((1-((2-amino-6-chloro-9h-purin-9-yl)methyl)cyclopropyl)oxy)methyl-phosphonate | |
| HK40053356A (en) | Method of manufacturing a solid form of a bet bromodomain inhibitor | |
| EA043992B1 (ru) | Способ изготовления твердой формы ингибитора бромодомена bet | |
| HK1158630A (en) | Phenyl-alkyl piperazines having a modulating activity of tnf |